Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

The FDA approved Keytruda (pembrolizumab), which is a PD ... Hodgkin lymphoma may have already been taking the drug off-label ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial ... Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Keytruda has been the best-selling medicine ... Not everything will make it to market, but I expect many brand-new approvals and label expansions through 2029. There is one crucial headwind ...

open-label trial involved 704 treatment-naïve patients with newly diagnosed stage III or IVA resected, locally advanced HNSCC (LA-HNSCC). The study's design included KEYTRUDA as a neoadjuvant ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

ImmunityBio has around $130.1 million in cash, enough to fund operations for at least the next 12 months. Read why I'm very ...